论文部分内容阅读
目的:比较氨氯地平联合替米沙坦和氨氯地平联合复方阿米洛利对轻中度原发性高血压患者的降压疗效和不良反应。方法:选择96例轻、中度原发性高血压患者,按随机及平行对照原则分为氨氯地平/复方阿米洛利组(A组)48例和氨氯地平/替米沙坦组(B组)48例,分别观察两组降压疗效,血生化指标影响及不良反应。观察时间12个月。结果:两组用药后收缩压和舒张压均有显著下降,组间比较差异无统计学意义(P>0.05)。两组治疗前后肝、肾功能及血糖等指标均无变化。A组治疗6月时血钾无变化,12月时血钾升高,6月和12月时尿酸均较入组时明显升高(P<0.05);B组治疗6月和12月时血钾及尿酸较入组时均无明显变化。B组不良反应发生率明显低于A组(P<0.05)。结论:氨氯地平联合替米沙坦与氨氯地平联合复方阿米洛利均有显著的降压效果。氨氯地平联合复方阿米洛利组不良反应发生率明显高于氨氯地平联合替米沙坦组。氨氯地平联合替米沙坦是更优化的联合治疗方案。
Objective: To compare the antihypertensive effects and side effects of amlodipine combined with telmisartan and amlodipine in combination with amiloride on patients with mild to moderate essential hypertension. Methods: Ninety-six patients with mild to moderate essential hypertension were divided into amlodipine / amiloride group (group A) 48 and amlodipine / telmisartan group according to randomized and parallel control principle (Group B) 48 cases were observed in two groups antihypertensive efficacy, blood biochemical indicators and adverse reactions. Observation time of 12 months. Results: The systolic and diastolic blood pressures decreased significantly after treatment in both groups, with no significant difference between the two groups (P> 0.05). Before and after treatment of liver and kidney function and blood glucose and other indicators were not changed. In group A, there was no change in serum potassium at 6 months, serum potassium at 12 months, and uric acid in June and December were significantly higher than those in group A (P <0.05); Group B was treated at 6 and 12 months There was no significant change of potassium and uric acid in the group. The incidence of adverse reactions in group B was significantly lower than that in group A (P <0.05). Conclusion: Amlodipine combined with telmisartan and amlodipine combined with amiloride has a significant antihypertensive effect. The incidence of adverse reactions in amlodipine combined with amiloride group was significantly higher than that in amlodipine combined with telmisartan group. Amlodipine combined with telmisartan is a more optimized combination regimen.